Sorry, you need to enable JavaScript to visit this website.
Pfizer Oncology
Loading...

The safety and efficacy of this agent(s), or use in this setting, has not been established or is subject to confirmation. For an agent(s) whose safety and efficacy has not been established or confirmed, future regulatory approval or commercial availability is not guaranteed.

Glycoprotein-NMB Directed Antibody Drug Conjugate

Geo Regions

Important Notice Regarding the Scientific Information You Have Requested

You are being redirected to the scientific presentations section. The information provided here relate to investigational assets. The safety and efficacy of the unapproved assets has not been proven. 

Please acknowledge that you understand this before proceeding.

Glycoprotein-NMB Directed Antibody Drug Conjugate

PF-08046033 |GPS is an investigational compound. Its safety and efficacy have not been established.

Share to an HCP

Overview + Rationale

RATIONALE FOR CANCER TARGET1-6

  • GPNMB is a type 1a transmembrane protein that is markedly upregulated in various malignancies
  • GPNMB is associated with poor patient prognosis and plays diverse roles in cancer biology, contributing to processes such as cell differentiation, proliferation, invasion, and migration.
  • Low GPNMB expression in normal tissues, contrasted with high expression in primary and metastatic tumors, makes GPNMB a compelling target for antibody-drug conjugate (ADC) therapies.

 

OVERVIEW1

  • PF-08046033 | GPS is an investigational GPNMB targeting ADC with a novel Auristatin S payload
  • PF-08046033 | GPS is composed of the human IgG1 anti-GPNMB mAb (hCR011) conjugated to the novel microtubule disrupting agent AurS using the clinical validated, protease-cleavable MC-Val-Cit linker with an average drug-to-antibody ratio (DAR) of 4

Mechanism of Action

Stage of Development

Other

Advanced Solid Tumors

Phase 1 Monotherapy
This information is current as of August 4th 2026.

ADC=antibody drug conjugate; GPNMB=glycoprotein non-metastatic melanoma protein B

REFERENCES: 1. Katoch P et al. Abstract 1673: Cancer Research. 86. 1673-1673. 10.1158/1538-7445.AM2026-1673; 2. Taya and Hammes. Steroids. 2018;133(102-107). ; 3. Long C. et al. Front Mol Biosci. 2025;12(1664764). ; 4. Vahdat et al. Breast Cancer. 2021;7(57). ; 5. Liguori et al. Cell Mol Immunol. 2021;18(711-722). ; 6. Zhai et al. Oncol Lett. 2022;23(36). ; 7.NCT07519655 https://clinicaltrials.gov/study/NCT07519655 Updated April 23, 2026. Accessed July 16, 2026.